Efficacy and safety of silymarin containing antioxidant serum as an adjuvant treatment of mild-to-moderate acne vulgaris: A prospective, open-label pilot study

被引:9
|
作者
Kim, Jemin [1 ]
Lee, Yun Na [1 ]
Lee, Joohee [1 ]
Lee, Sang Gyu [1 ]
Kim, Hyun [2 ]
Choi, Ye Seul [2 ]
Draelos, Zoe Diana [3 ]
Kim, Jihee [1 ,2 ]
机构
[1] Yonsei Univ, Severance Hosp, Cutaneous Biol Res Inst, Dept Dermatol,Coll Med, Seoul, South Korea
[2] Yonsei Univ, Yongin Severance Hosp, Dept Dermatol, Coll Med, Seoul, South Korea
[3] Dermatol Consulting Serv, Durham, NC USA
关键词
acne; cosmeceutical; oral isotretinoin; silymarin; SALICYLIC-ACID; DERMOCOSMETICS;
D O I
10.1111/jocd.15439
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Silymarin is the active component of milk thistle, which has antioxidant properties by scavenging free radicals and potential comedolytic properties. Aims This study aimed to assess the efficacy and safety of 0.5% silymarin-loaded antioxidant serum (SAS) used to treat mild-to-moderate acne. Patients and Methods A prospective, open-label pilot study was conducted. We enrolled 22 Korean acne patients who applied the 0.5% SAS on the whole face twice daily while continuing the current anti-acne medications. Grade of acne severity, individual lesion counts, sebum output levels, skin erythema, and melanin pigmentation were assessed. Results After a 4-week application, the modified Global Acne Grading Score (mGAGS), Global Evaluation Acne (GEA) scale, and the acne lesion counts were significantly decreased. Sebum secretion, skin pigmentation, and erythema were also reduced during the study period, yet only the melanin pigmentation index reached statistical significance. Subgroup analysis revealed that the patients who took the low-dose oral isotretinoin during the study period showed more noticeable improvements in skin sebum output and melanin pigmentation. Additionally, no adverse event was associated with using the 0.5% SAS. Conclusion The 0.5% silymarin-containing antioxidant formulation improved acne's clinical severity and related skin biophysical parameters.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 50 条
  • [31] An open study to determine the efficacy of blue light in the treatment of mild to moderate acne
    Morton, CA
    Scholefield, RD
    Whitehurst, C
    Birch, J
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2005, 16 (04) : 219 - 223
  • [32] Efficacy and safety of hydrogen peroxide cream alone or in combination with salicilyc foam in the treatment of mild-to-moderate acne
    Milani, M
    Bigardi, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P16 - P16
  • [33] An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer's Disease
    Gordon, Marc L.
    Christen, Erica
    Keehlisen, Lynda
    Gong, Michelle
    Lam, Fung
    Giliberto, Luca
    Gomar, Jesus J.
    Koppel, Jeremy
    JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2024, 8 (01) : 1111 - 1114
  • [34] Beclomethasone dipropionate for the treatment of mild-to-moderate crohn's disease: An open-label, budesonide-controlled, randomized study
    Tursi, A
    Giorgetti, GM
    Brandimarte, G
    Elisei, W
    Aiello, F
    MEDICAL SCIENCE MONITOR, 2006, 12 (06): : PI29 - PI32
  • [35] Pilot study of the efficacy and safety of infrared tight in the treatment of inflammatory acne vulgaris
    Gupta, Aditya
    Vasily, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB23 - AB23
  • [36] A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris
    Heffernan, M. P.
    Nelson, M. M.
    Anadkat, M. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (03) : 548 - 552
  • [37] Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study
    Yukari Okubo
    Hidetoshi Takahashi
    Ryosuke Hino
    Koki Endo
    Satoru Kikuchi
    Yasushi Ozeki
    Taichi Nakamura
    Maria Paris
    Masatoshi Abe
    Dermatology and Therapy, 2022, 12 : 1469 - 1480
  • [39] Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study
    Okubo, Yukari
    Takahashi, Hidetoshi
    Hino, Ryosuke
    Endo, Koki
    Kikuchi, Satoru
    Ozeki, Yasushi
    Nakamura, Taichi
    Paris, Maria
    Abe, Masatoshi
    DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1469 - 1480
  • [40] Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study
    Anderson, I. M.
    Sarsfield, A.
    Haddad, P. M.
    JOURNAL OF AFFECTIVE DISORDERS, 2009, 117 (1-2) : 116 - 119